Frontiers in Oncology | Cancer Immunity and Immunotherapy

Case Report

Published on 10 May 2024

Case report: Regression of in-transit metastases of cutaneous squamous cell carcinoma with combination pembrolizumab and topical diphencyprone

in Cancer Immunity and Immunotherapy

Dina Poplausky
Jade N. Young
Brandon R. Block
Yeriel Estrada
Giselle K. Singer
Vicky Wong
Patricia Cabral
Yamato Suemitsu
Randie H. Kim
Philip Friedlander

Frontiers in Oncology

doi 10.3389/fonc.2024.1294331

1,309 views

Case Report

Published on 10 May 2024

Case report: Long-term intracranial effect of zimberelimab monotherapy following surgical resection of high PD-L1-expressing brain metastases from NSCLC

in Cancer Immunity and Immunotherapy

Weijia Wu
Jinyou Guo
Lianxiang He
Qi Deng
Xianping Huang

Frontiers in Oncology

doi 10.3389/fonc.2024.1390343

1,210 views
1 citation

Case Report

Published on 10 May 2024

Case report: Massive hepatocellular carcinoma with complete response to the non-surgical systematic treatment strategy

in Cancer Immunity and Immunotherapy

Yun Li
Yanzhen Lai
Xuqiang Luo
Jian Wu
Kunpeng Wu
Haiqing Ma

Frontiers in Oncology

doi 10.3389/fonc.2024.1291131

1,967 views

Original Research

Published on 08 May 2024

Examination of the role of mutualism in immune evasion

in Cancer Immunity and Immunotherapy

Lucie Gourmet
Simon Walker-Samuel
Parag Mallick

Frontiers in Oncology

doi 10.3389/fonc.2024.1406744

1,079 views
1 citation

Systematic Review

Published on 02 May 2024

The risk of endocrine immune-related adverse events induced by PD-1 inhibitors in cancer patients: a systematic review and meta-analysis

in Cancer Immunity and Immunotherapy

Pengfei Zhao
Ting Zhao
Lihong Yu
Wenming Ma
Wenyu Liu
Chenning Zhang

Frontiers in Oncology

doi 10.3389/fonc.2024.1381250

3,196 views
2 citations

Original Research

Published on 02 May 2024

Predictive value of PD-L1 and TMB for short-term efficacy prognosis in non-small cell lung cancer and construction of prediction models

in Cancer Immunity and Immunotherapy

Shuling Shi
Yingyi Wang
Jingjing Wu
Boya Zha
Peihong Li
Yukun Liu
Yuchuan Yang
Jinglin Kong
Shibo Gao
Haiyang Cui

Frontiers in Oncology

doi 10.3389/fonc.2024.1342262

1,696 views

Original Research

Published on 02 May 2024

Increased co-expression of 4-1BB with PD-1 on CD8+ tumor-infiltrating lymphocytes is associated with improved prognosis and immunotherapy response in cervical cancer

in Cancer Immunity and Immunotherapy

Xiaonan Zhu
Yaning Feng
Peiwen Fan
Danning Dong
Jianlin Yuan
Cheng Chang
Ruozheng Wang

Frontiers in Oncology

doi 10.3389/fonc.2024.1381381

1,971 views
1 citation

Original Research

Published on 01 May 2024

High immune cell infiltration predicts improved survival in cholangiocarcinoma

in Cancer Immunity and Immunotherapy

Erkki-Ville Wirta
Säde Szeto
Hanna Koppatz
Arno Nordin
Heikki Mäkisalo
Johanna Arola
Jukka Sirén
Maarit Ahtiainen
Jan Böhm
Jukka-Pekka Mecklin

Frontiers in Oncology

doi 10.3389/fonc.2024.1333926

1,568 views
4 citations

Original Research

Published on 29 Apr 2024

Chordoma cancer stem cell subpopulation characterization may guide targeted immunotherapy approaches to reduce disease recurrence

in Cancer Immunity and Immunotherapy

Diana C. Lopez
Kellsye P. Fabian
Michelle R. Padget
Yvette L. Robbins
Joshua T. Kowalczyk
Wiem Lassoued
Danielle M. Pastor
Clint T. Allen
Gary L. Gallia
James L. Gulley

Frontiers in Oncology

doi 10.3389/fonc.2024.1376622

2,515 views

Editorial

Published on 15 Apr 2024

Editorial: Emerging learnings in cell therapy: novel binding domains, universal CAR-T cells, and more

in Cancer Immunity and Immunotherapy

Anand Rotte

Frontiers in Oncology

doi 10.3389/fonc.2024.1404376

944 views

Review

Published on 10 Apr 2024

The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma

in Cancer Immunity and Immunotherapy

Yan Lu
Bo Lin
Mengsen Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1363695

3,477 views
7 citations

Case Report

Published on 05 Apr 2024

Retreatment with immunotherapy in a patient with hepatocellular carcinoma who received immune checkpoint inhibitors after primary curative treatment: a case report

in Cancer Immunity and Immunotherapy

Tao Wang
Fei Tang
Fenghui Li
Weili Yin
Jing Liang

Frontiers in Oncology

doi 10.3389/fonc.2024.1321195

1,193 views

Original Research

Published on 03 Apr 2024

VISTA/CTLA4/PD1 coexpression on tumor cells confers a favorable immune microenvironment and better prognosis in high-grade serous ovarian carcinoma

in Cancer Immunity and Immunotherapy

Aida Jlassi
Rim Rejaibi
Maroua Manai
Ghada Sahraoui
Fatma Zahra Guerfali
Lamia Charfi
Amel Mezlini
Mohamed Manai
Karima Mrad
Raoudha Doghri

Frontiers in Oncology

doi 10.3389/fonc.2024.1352053

1,995 views
2 citations

Systematic Review

Published on 03 Apr 2024

Comparative efficacy and safety of targeted therapy and immunotherapy for HER2-positive breast cancer: a systematic review and network meta-analyses

in Cancer Immunity and Immunotherapy

Suyu Gu
Yuting Liu
Yufan Huang
Wenzheng Lin
Ke Li

Frontiers in Oncology

doi 10.3389/fonc.2024.1331055

2,194 views

Case Report

Published on 28 Mar 2024

Optimal response to tislelizumab plus chemotherapy in metastatic triple-negative breast cancer: a case report and literature review

in Cancer Immunity and Immunotherapy

Yuxin Ma
Xinhong Shi
Kun Zhao
Shuyi Hu
Yue Shi
Yingying Jiang
Yiling Liu
Lin Lu
Yuting Chang
Fei Zhou

Frontiers in Oncology

doi 10.3389/fonc.2024.1328844

1,800 views

Study Protocol

Published on 28 Mar 2024

FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion

in Cancer Immunity and Immunotherapy

Christopher Hackenbruch
Jens Bauer
Jonas S. Heitmann
Yacine Maringer
Annika Nelde
Monika Denk
Lisa Zieschang
Christine Kammer
Birgit Federmann
Susanne Jung

Frontiers in Oncology

doi 10.3389/fonc.2024.1367450

3,318 views
4 citations